Last reviewed · How we verify
Health Research, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Experimental Cyclic Regimen | Experimental Cyclic Regimen | marketed | Small molecule | Cardiovascular | ||
| Standard Clinical Practice Regimen | Standard Clinical Practice Regimen | marketed | SSRI | SERT, NET | Psychiatry |
Therapeutic area mix
- Cardiovascular · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Akorn, Inc. · 1 shared drug class
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- Beni-Suef University · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- Centre of Clinical Pharmacology, Hanoi Medical University · 1 shared drug class
- Chonbuk National University Hospital · 1 shared drug class
- Abivax S.A. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Health Research, Inc.:
- Health Research, Inc. pipeline updates — RSS
- Health Research, Inc. pipeline updates — Atom
- Health Research, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Health Research, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/health-research-inc. Accessed 2026-05-17.